Tingting Fu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tingting Fu has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
- Feng Zhu
Zhejiang University
6 shared publications - Haibin Dai
Department of Pharmacy, The Second Affiliated Hospital, Zhejiang University School of Medicine
3 shared publications Minjie Mou
College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China
3 shared publications- Yintao Zhang
College of Pharmaceutical Sciences, The Second Affiliated Hospital, Zhejiang University School of Medicine, State Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University , Hangzhou 310058
3 shared publications Hao Yang
2 shared publications- Lianyi Han
Department of Dermatology, Huashan Hospital, Shanghai Institute of Dermatology, Fudan University, Shanghai, China.
2 shared publications
Latest Publications
- 24 June 2026
- Published by Springer Nature in Nature Protocols
- Vol. 21 (11) , 5548-5567
Facilitating structure-based drug discovery with an artificial intelligence-driven virtual screening platform
Structure-based virtual screening (VS) via molecular docking is a pivotal approach for hit identification. Many artificial intelligence (AI)-powered protein–ligand docking and scoring methods have demonstrated impressive speed and accuracy. Retrospective benchmarking studies using enrichment rate and computational efficiency on curated datasets have corroborated their potential for discovering bioactive compounds. However, determining which method suits a specific application and implementing it efficiently remains challenging. Here we present the Comprehensive VS Platform with AI Engine (CVSP-AIE) for drug discovery from compound libraries. It integrates three AI models: KarmaDock, a fast docking model that directly updates atomic coordinates; CarsiDock, an accurate docking model that predicts protein–ligand distances and reconstructs binding poses; and RTMScore, an accurate scoring model that learns residue–atom distance distributions for affinity prediction. Their hierarchical application enables dynamical balances in screening speed and accuracy. CVSP-AIE is available as an online web server (https://cadd.zju.edu.cn/cvsp/) and a local software package. Users can efficiently initiate drug screening by uploading a protein and a known binder that defines the binding pocket. The following workflow involves (1) preprocessing, including protein structure repair and molecule standardization, (2) binding pose and affinity prediction powered by KarmaDock, CarsiDock and RTMScore and (3) postprocessing, comprising protein–ligand interaction calculation and visualization. It takes 30–45 min to hierarchically screen 100,000 compounds, and the output is a ranked list of molecules with predicted binding scores, intermolecular interaction profiles and interactive chemical space analysis. Users can also install locally the hierarchical screening module through command-line package for arbitrary-scale screening.
- 24 June 2026
- Published by Springer Nature in Nature Protocols
- Vol. 21 (11) , 5548-5567
Facilitating structure-based drug discovery with an artificial intelligence-driven virtual screening platform
Structure-based virtual screening (VS) via molecular docking is a pivotal approach for hit identification. Many artificial intelligence (AI)-powered protein–ligand docking and scoring methods have demonstrated impressive speed and accuracy. Retrospective benchmarking studies using enrichment rate and computational efficiency on curated datasets have corroborated their potential for discovering bioactive compounds. However, determining which method suits a specific application and implementing it efficiently remains challenging. Here we present the Comprehensive VS Platform with AI Engine (CVSP-AIE) for drug discovery from compound libraries. It integrates three AI models: KarmaDock, a fast docking model that directly updates atomic coordinates; CarsiDock, an accurate docking model that predicts protein–ligand distances and reconstructs binding poses; and RTMScore, an accurate scoring model that learns residue–atom distance distributions for affinity prediction. Their hierarchical application enables dynamical balances in screening speed and accuracy. CVSP-AIE is available as an online web server (https://cadd.zju.edu.cn/cvsp/) and a local software package. Users can efficiently initiate drug screening by uploading a protein and a known binder that defines the binding pocket. The following workflow involves (1) preprocessing, including protein structure repair and molecule standardization, (2) binding pose and affinity prediction powered by KarmaDock, CarsiDock and RTMScore and (3) postprocessing, comprising protein–ligand interaction calculation and visualization. It takes 30–45 min to hierarchically screen 100,000 compounds, and the output is a ranked list of molecules with predicted binding scores, intermolecular interaction profiles and interactive chemical space analysis. Users can also install locally the hierarchical screening module through command-line package for arbitrary-scale screening.
- Open Access
- 3 February 2026
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (7) , 4128-4146
Unveiling the bioactive landscape of drug inactive ingredients (DIGs) using deep transfer learning
- 3 February 2026
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (7) , 4128-4146
Open AccessUnveiling the bioactive landscape of drug inactive ingredients (DIGs) using deep transfer learning
- Open Access
- 11 November 2025
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (D1) , D1556-D1568
PersADE: a database of personalized adverse drug events and their underlying molecular mechanisms
As a major burden on global healthcare systems, adverse drug events (ADEs) result in significant morbidity, mortality, and healthcare resource consumption. With the rapid advances in precision medicine, personalized ADEs and their molecular mechanisms are important components of drug repurposing and drug safety improvement. Thus, extensive studies have been conducted to collect valuable information on personalized ADEs, but no database has yet been available to provide such data. In this work, PersADE, a database aiming to provide personalized drug adverse events and their molecular mechanisms, was constructed. It integrated 4 061 772 personalized drug-ADE associations, 31 756 protein-ADE associations, and 108 677 drug-protein interactions, with a particular emphasis on off-target effects. The uniqueness of these data lies in (a) providing demographic characteristics, disease context and drug administration parameters associated with ADEs, enabling stratification of drug-ADE associations; (b) systematically integrating interactions among drugs, human proteins and ADEs, describing the mechanistic insights. Given the growing global focus on precision medicine, PersADE is highly anticipated to significantly impact studies on personalized ADEs and mechanistic explorations by providing researchers and clinicians with evidence-based tools. It is now freely accessible at: https://idrblab.org/PersADE
- 11 November 2025
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (D1) , D1556-D1568
Open AccessPersADE: a database of personalized adverse drug events and their underlying molecular mechanisms
As a major burden on global healthcare systems, adverse drug events (ADEs) result in significant morbidity, mortality, and healthcare resource consumption. With the rapid advances in precision medicine, personalized ADEs and their molecular mechanisms are important components of drug repurposing and drug safety improvement. Thus, extensive studies have been conducted to collect valuable information on personalized ADEs, but no database has yet been available to provide such data. In this work, PersADE, a database aiming to provide personalized drug adverse events and their molecular mechanisms, was constructed. It integrated 4 061 772 personalized drug-ADE associations, 31 756 protein-ADE associations, and 108 677 drug-protein interactions, with a particular emphasis on off-target effects. The uniqueness of these data lies in (a) providing demographic characteristics, disease context and drug administration parameters associated with ADEs, enabling stratification of drug-ADE associations; (b) systematically integrating interactions among drugs, human proteins and ADEs, describing the mechanistic insights. Given the growing global focus on precision medicine, PersADE is highly anticipated to significantly impact studies on personalized ADEs and mechanistic explorations by providing researchers and clinicians with evidence-based tools. It is now freely accessible at: https://idrblab.org/PersADE
- 16 October 2025
- Published by Springer Nature in Nature Protocols
- Vol. 21 (3) , 1235-1261
Navigating the data processing for cytometry-based single-cell proteomics
Cytometry-based single-cell proteomics (SCP) has emerged as a powerful technique that greatly advances our understanding of complex biological systems with a new level of granularity. Various methods have been developed to process cytometry-based SCP data. However, it remains extremely challenging to identify the well-performing processing workflows for specific datasets. Here, we develop ANPELA, an out-of-the-box method for navigating the proteomic data processing based on large-scale screening. It enables a comparison among the performances of thousands of the processing workflows in identifying cell subpopulations and inferring pseudo-time trajectories based on machine learning. Several cases are then analyzed, highlighting its ability to identify the optimal ways of data processing for cytometry-based SCP studies. A new package is also deployed to ensure multiscenario usability (such as desktop software, R package and online server), data security (enabling local and open-source execution) and a user-friendly interface (realizing interactive and visualizable applications). Overall, ANPELA can be utilized by a broad audience, including those without coding skills, and is freely accessible and downloadable at https://idrblab.org/anpela/. Its execution time may range from minutes to hours depending on the size of the analyzed data.
- 16 October 2025
- Published by Springer Nature in Nature Protocols
- Vol. 21 (3) , 1235-1261
Navigating the data processing for cytometry-based single-cell proteomics
Cytometry-based single-cell proteomics (SCP) has emerged as a powerful technique that greatly advances our understanding of complex biological systems with a new level of granularity. Various methods have been developed to process cytometry-based SCP data. However, it remains extremely challenging to identify the well-performing processing workflows for specific datasets. Here, we develop ANPELA, an out-of-the-box method for navigating the proteomic data processing based on large-scale screening. It enables a comparison among the performances of thousands of the processing workflows in identifying cell subpopulations and inferring pseudo-time trajectories based on machine learning. Several cases are then analyzed, highlighting its ability to identify the optimal ways of data processing for cytometry-based SCP studies. A new package is also deployed to ensure multiscenario usability (such as desktop software, R package and online server), data security (enabling local and open-source execution) and a user-friendly interface (realizing interactive and visualizable applications). Overall, ANPELA can be utilized by a broad audience, including those without coding skills, and is freely accessible and downloadable at https://idrblab.org/anpela/. Its execution time may range from minutes to hours depending on the size of the analyzed data.
- Open Access
- 2 October 2025
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (D1) , D1702-D1710
VARIDT 4.0: distribution variability of drug transporters
The multilevel distribution variability of drug transporters—from tissues to cells and organelles—is critical for understanding drug response, drug–drug interactions, and multidrug resistance. The absorption, dispersion, metabolism, and excretion properties of drugs are codetermined by these multilevel distribution patterns, including tissue-specific expression, cellular heterogeneity, and subcellular localization. However, a public database that systematically integrates these crucial data of drug transporter distribution variability has been lacking. Therefore, in this major update, VARIDT 4.0 was developed to provide a comprehensive resource, incorporating 25 797 tissue-level expression profiles, 451 830 cell-level expression records, and 1034 subcellular localization entries. Additionally, the foundational modules on general, structural, and regulatory variability were extensively updated. This multilevel variability data is highly relevant to the transport of 889 approved and 221 clinical trial drugs, as well as 689 endogenous metabolites, implicated in the treatment of 558 diseases. Furthermore, by integrating these new distribution layers with its existing data, VARIDT 4.0 now enables comprehensive consideration of how a transporter’s function is modulated by its specific spatiotemporal context. Overall, VARIDT 4.0 is expected to be a valuable data repository for system pharmacology, serving as an essential complement to existing pharmaceutical databases, and is freely accessible without login at https://idrblab.org/varidt/.
- 2 October 2025
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (D1) , D1702-D1710
Open AccessVARIDT 4.0: distribution variability of drug transporters
The multilevel distribution variability of drug transporters—from tissues to cells and organelles—is critical for understanding drug response, drug–drug interactions, and multidrug resistance. The absorption, dispersion, metabolism, and excretion properties of drugs are codetermined by these multilevel distribution patterns, including tissue-specific expression, cellular heterogeneity, and subcellular localization. However, a public database that systematically integrates these crucial data of drug transporter distribution variability has been lacking. Therefore, in this major update, VARIDT 4.0 was developed to provide a comprehensive resource, incorporating 25 797 tissue-level expression profiles, 451 830 cell-level expression records, and 1034 subcellular localization entries. Additionally, the foundational modules on general, structural, and regulatory variability were extensively updated. This multilevel variability data is highly relevant to the transport of 889 approved and 221 clinical trial drugs, as well as 689 endogenous metabolites, implicated in the treatment of 558 diseases. Furthermore, by integrating these new distribution layers with its existing data, VARIDT 4.0 now enables comprehensive consideration of how a transporter’s function is modulated by its specific spatiotemporal context. Overall, VARIDT 4.0 is expected to be a valuable data repository for system pharmacology, serving as an essential complement to existing pharmaceutical databases, and is freely accessible without login at https://idrblab.org/varidt/.
- Open Access
- 9 April 2025
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 15 (6) , 101298
druglikeFilter 1.0: An AI powered filter for collectively measuring the drug-likeness of compounds
- 9 April 2025
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 15 (6) , 101298
Open AccessdruglikeFilter 1.0: An AI powered filter for collectively measuring the drug-likeness of compounds
- Open Access
- 5 March 2025
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 15 (8)
LocPro: A deep learning-based prediction of protein subcellular localization for promoting multi-directional pharmaceutical research
- 5 March 2025
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 15 (8)
Open AccessLocPro: A deep learning-based prediction of protein subcellular localization for promoting multi-directional pharmaceutical research
- Open Access
- 7 October 2024
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 53 (D1) , D1683-D1691
MolBiC: the cell-based landscape illustrating molecular bioactivities
The measurement of cell-based molecular bioactivity (CMB) is critical for almost every step of drug development. With the booming application of AI in biomedicine, it is essential to have the CMB data to promote the learning of cell-based patterns for guiding modern drug discovery, but no database providing such information has been constructed yet. In this study, we introduce MolBiC, a knowledge base designed to describe valuable data on molecular bioactivity measured within a cellular context. MolBiC features 550 093 experimentally validated CMBs, encompassing 321 086 molecules and 2666 targets across 988 cell lines. Our MolBiC database is unique in describing the valuable data of CMB, which meets the critical demands for CMB-based big data promoting the learning of cell-based molecular/pharmaceutical pattern in drug discovery and development. MolBiC is now freely accessible without any login requirement at: https://idrblab.org/MolBiC/.
- 7 October 2024
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 53 (D1) , D1683-D1691
Open AccessMolBiC: the cell-based landscape illustrating molecular bioactivities
The measurement of cell-based molecular bioactivity (CMB) is critical for almost every step of drug development. With the booming application of AI in biomedicine, it is essential to have the CMB data to promote the learning of cell-based patterns for guiding modern drug discovery, but no database providing such information has been constructed yet. In this study, we introduce MolBiC, a knowledge base designed to describe valuable data on molecular bioactivity measured within a cellular context. MolBiC features 550 093 experimentally validated CMBs, encompassing 321 086 molecules and 2666 targets across 988 cell lines. Our MolBiC database is unique in describing the valuable data of CMB, which meets the critical demands for CMB-based big data promoting the learning of cell-based molecular/pharmaceutical pattern in drug discovery and development. MolBiC is now freely accessible without any login requirement at: https://idrblab.org/MolBiC/.